Montelukast Sodium Market Revenue to Attain USD 1.88 Bn by 2035

Montelukast Sodium Market Revenue and Trends 2026 to 2035

The global montelukast sodium market revenue was valued at USD 1.07 billion in 2025 and is expected to attain around USD 1.88 billion by 2035, growing at a CAGR of 5.80% during forecast period. The market growth is driven by the rising prevalence of asthma and the increasing acceptance of convenient oral maintenance therapy for managing respiratory conditions.

The Montelukast Sodium Market: A Solution to Asthma and Allergic Rhinitis

Montelukast sodium remains a key treatment option, offering long-term benefits for patients with asthma. The market is characterized by a variety of oral dosage forms, including tablets, chewables, and granules, which are widely available in hospitals and local pharmacies. The rising demand for long-term management solutions rather than emergency treatment, and the availability of competitive generic alternatives, all of which significantly impact market growth.

The application of montelukast sodium extends beyond standard treatment recommendations to include pediatric asthma management, seasonal allergy care, and long-term respiratory management, providing a broad spectrum of dosage forms and distribution methods. Additionally, the rising development of new formulations and innovative therapeutic approaches drives the market.

Future Growth Prospects of the Montelukast Sodium Market

Increasing Prescription Rate

The rising prevalence of asthma and allergic rhinitis, coupled with an aging population, is expected to drive the demand for oral maintenance therapies that are easier for patients to adhere to, facilitating long-term prescriptions. As these conditions become more common, the need for consistent and effective treatments grows, further boosting montelukast sodium’s market presence.

Formulation Innovation

Growing development of novel formulations, such as quick-dissolving formulations, particularly those suitable for children, is expected to drive the market. These innovative formulations are increasingly being recognized as crucial for improving patient adherence, demonstrating that convenience is becoming as valuable as clinical efficacy in treatment options.

Preventive Use Over Acute Care

Montelukast’s role has evolved from treating symptoms to also preventing them, particularly in asthma care. This shift toward preventive treatment is not only increasing prescription frequency and duration but is also broadening the market without the need for new drug classes, highlighting montelukast's growing importance in long-term respiratory management.

Market Statistics Behind Montelukast Sodium

Montelukast sodium is one of the most commonly prescribed medications and remains a very predictable member of the market. It was prescribed for around 25.9 million prescriptions in the U.S. in 2023, helping nearly 6.5 million patients and being one of the top 20 most dispensed medications in the country.

From a financial perspective, montelukast offers significant accessibility, with an average prescription cost of about $19.79, and patients typically paying around $7.59 out-of-pocket for therapy, which amounts to less than fifty cents per day. However, it's important to note that montelukast completely dominates its pharmacological class, accounting for nearly 100% of leukotriene receptor antagonist prescriptions. This dominance highlights a market driven more by its long-established clinical use and efficacy than by competitive forces.

Market Segmentation Overview

• By Dosage Form: The tablets segment held the largest share of 70% in the montelukast sodium market in 2025. This is due to their ease of administration and wide acceptance across all ages. Their patient compliance has made them the standard prescription for asthma and allergic rhinitis treatment, improving adherence without altering behavior.
• By Dosage Form: The oral granules segment was the second-largest shareholder in 2025 and is expected to grow at the fastest CAGR during the forecast period. This is due to their ease of consumption and flexible dosing, which has alleviated resistance among younger patients. Oral granules are becoming an increasingly popular choice for pediatric and elderly patients alike.
• By Application: The asthma segment held a major revenue share of 50% in the market in 2025, driven by the chronic nature of the condition and the reliance on long-term maintenance therapies. Montelukast has become a preferred choice for many patients for long-term treatment, and its consistent usage has been further facilitated by the global increase in asthma prevalence.
• By Application: The allergic rhinitis segment is expected to grow at the fastest rate between 2026 and 2035, primarily due to the rising prevalence of seasonal allergies and respiratory issues linked to pollution. This growth is driven by the recurrence of symptoms rather than their severity, as repeated exposure to allergens has led to a growing demand for effective, consistent symptom control over time.
• By Distribution Channel: The retail pharmacies segment held a 45% share of the montelukast sodium market in 2025 because of their convenience and ability to handle large volumes of outpatient prescriptions. These pharmacies play a crucial role in providing ongoing treatment for chronic conditions like asthma, ensuring patients have uninterrupted access to their medications.
• By Distribution Channel: The hospital pharmacies segment was the second-largest shareholder, holding a 40% share in 2025, and is expected to grow at a significant rate over the projection period. This growth is attributed to their specialized focus on prescription dispensing in clinical settings, where they are integral to managing moderate to severe respiratory disorders. The structured healthcare approach, along with regulated access and continuous monitoring, enhances the effectiveness of treatments in these settings.

Regional Analysis

North America dominated the global montelukast sodium market with a share of 35% in 2025, driven by the high prevalence of asthma and allergic diseases, as well as the availability of diagnostic and ongoing treatment options in the pharmaceutical pipeline. The U.S. accounts for the majority of the share, supported by structured insurance plans and strong adherence to prescriptions, ensuring stable medication volumes. Canada follows closely, experiencing steady growth due to accessible public healthcare services and an increasing number of allergy cases, particularly in urban populations.

Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period because of the decline in air quality and rising respiratory diseases, which are boosting the demand for maintenance therapies like montelukast. With the growing population and pollution-related asthma cases, particularly in countries like India and China, there is a high demand for montelukast sodium. Additionally, Japan and South Korea play key roles in the market, due to their focus on enhancing access to care and addressing the needs of aging populations.

Montelukast Sodium Market Coverage

Top Companies in the Montelukast Sodium Market

Merck & Co., Inc. has been a leader in the montelukast sodium market, setting the standard for pioneering work in its field. Generic drug companies like Teva Pharmaceutical Industries Ltd., Mylan N.V., and Sandoz have played a crucial role in increasing medication accessibility, making montelukast more affordable and widely available. Major Indian pharmaceutical companies such as Sun Pharmaceutical Industries Ltd., Cipla Limited, and Dr. Reddy’s Laboratories Ltd. are leveraging their strengths in volume and cost-effectiveness to influence global supply chains. Additionally, companies like Aurobindo Pharma Ltd. and Zydus Lifesciences Ltd. are expanding their reach with a range of formulations, while Lupin Limited and Glenmark Pharmaceuticals Ltd. continue to strengthen their positions by focusing on specialized respiratory product lines.

Segments Covered in the Report

By Dosage Form

• Tablets
• Film-coated Tablets
• Chewable Tablets
• Oral Granules
• Others

By Application

• Asthma
• Allergic Rhinitis
• Chronic Urticaria
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8293

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344